A prospective, open-label, single arm, multicentre study to evaluate efficacy, safety and acceptability of pericoital oral contraception using levonorgestrel 1.5 mg

Human Reproduction
Mario P R FestinNathalie Kapp

Abstract

Will the use of levonorgestrel (LNG) 1.5 mg taken at each day of coitus by women who have relatively infrequent sex be an efficacious, safe and acceptable contraceptive method? Typical use of LNG 1.5 mg taken pericoitally, before or within 24 h of sexual intercourse, provides contraceptive efficacy of up to 11.0 pregnancies per 100 women-years (W-Y) in the primary evaluable population and 7.1 pregnancies per 100 W-Y in the evaluable population. LNG 1.5 mg is an effective emergency contraception following unprotected intercourse. Some users take it repeatedly, as their means of regular contraception. This was a prospective, open-label, single-arm, multicentre Phase III trial study with women who have infrequent coitus (on up to 6 days a month). Each woman had a follow-up visit at 2.5, 4.5 and 6.5 months after admission or until pregnancy occurs if sooner, or she decided to interrupt participation. The study was conducted between 10 January 2012 and 15 November 2014. A total of 330 healthy fertile women aged 18-45 years at risk of pregnancy who reported sexual intercourse on up to 6 days a month, were recruited from four university centres located in Bangkok, Thailand; Campinas, Brazil; Singapore and Szeged, Hungary to use LNG 1....Continue Reading

References

Sep 1, 1991·International Journal of Gynaecology and Obstetrics : the Official Organ of the International Federation of Gynaecology and Obstetrics·C H HeP F Van Look
Jul 25, 2000·Journal of Clinical Pharmacy and Therapeutics·S Lerkiatbundit, W Reanmongkol
Jul 9, 2002·Obstetrics and Gynecology·Lena MarionsKristina Gemzell Danielsson
Dec 14, 2002·Lancet·Helena von HertzenUNKNOWN WHO Research Group on Post-ovulatory Methods of Fertility Regulation
Apr 24, 2004·Contraception·Lena MarionsKristina Gemzell-Danielsson
Jun 12, 2004·Human Reproduction Update·K Gemzell-Danielsson, L Marions
Apr 17, 2007·Contraception·Idris A OkewoleOlukayode A Dada
Feb 19, 2009·Best Practice & Research. Clinical Obstetrics & Gynaecology·James Trussell
Apr 7, 2009·Journal of Pediatric and Adolescent Gynecology·Melissa L GilliamElizabeth J Levey
Sep 21, 2010·Contraception·Olukayode A DadaUNKNOWN Nigerian Network for Reproductive Health Research and Training
Oct 12, 2010·Contraception·Kristina Gemzell-Danielsson
Apr 12, 2011·Contraception·James Trussell
Oct 24, 2012·Obstetrics and Gynecology·UNKNOWN Committee on Health Care for Underserved Women

❮ Previous
Next ❯

Citations

Jun 29, 2017·BJOG : an International Journal of Obstetrics and Gynaecology·S T CameronK Gemzell-Danielsson
Nov 7, 2018·Current Opinion in Obstetrics & Gynecology·Erica P Cahill, Paul D Blumenthal
Mar 13, 2020·Clinical Drug Investigation·Nattawut Leelakanok, Janthima Methaneethorn
Nov 8, 2018·International Journal of Reproductive Medicine·Celia M J Matyanga, Blessing Dzingirai
Sep 12, 2018·Contraception and Reproductive Medicine·Kristin O HaegerKelly Cleland
Jun 11, 2021·Studies in Family Planning·Elizabeth G HenryIqbal Shah
Apr 16, 2020·Best Practice & Research. Clinical Obstetrics & Gynaecology·Mario Philip R Festin

❮ Previous
Next ❯

Related Concepts

Related Feeds

Anemia

Anemia develops when your blood lacks enough healthy red blood cells. Anemia of inflammation (AI, also called anemia of chronic disease) is a common, typically normocytic, normochromic anemia that is caused by an underlying inflammatory disease. Here is the latest research on anemia.